Devices › System, endovascular graft, aortic aneurysm treatment
Device brand name · Mih system endovascular graft aortic aneurysm treatment
Zenith Alpha Thoracic Endovascular Graft Proximal Components: medical device reports filed with FDA
500 reports name it, 2016–2026. Manufacturer given most often on reports: William Cook Europe. Product code MIH.
- 500
- device reports naming the brand
- 0% of all MAUDE reports · about 48 a year
- 45
- reports, 12 months to August 2026
- 72 in the 12 months before
- 36%
- classified as malfunction
- 14.8% across the product code
- 8.2%
- classified as death, as reported
- 41 reports · not verified by FDA
FDA's MAUDE database holds 500 reports that name the brand "Zenith Alpha Thoracic Endovascular Graft Proximal Components" (mih system endovascular graft aortic aneurysm treatment), received between January 2016 and August 2026; the manufacturer given most often on reports is William Cook Europe. Spellings of one product vary from report to report.
45 reports arrived in the 12 months to August 2026, down 37% from 72 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (55.8%), malfunction (36%) and death (8.2%); across all system, endovascular graft, aortic aneurysm treatment reports (product code MIH) death is recorded in 9.8% and malfunction in 14.8%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are off-label use (19.4%), failure to advance (8.8%) and malposition of device (8.4%). The patient problems coded most often are clinical endoleak, appropriate clinical signs, symptoms and conditions term/code not available and thrombosis/thrombus. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 72,039 reports carrying product code MIH. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Off-label use | 97 | 19.4% | 1.1% |
| Failure to advance | 44 | 8.8% | 1.1% |
| Malposition of device | 42 | 8.4% | 3.9% |
| Device endoleak | 40 | 8% | 1.2% |
| Leak/splashthe device leaked | 38 | 7.6% | 33.8% |
| Improper or incorrect procedure or method | 37 | 7.4% | 1.3% |
| Obstruction of flow | 37 | 7.4% | 1% |
| Patient device interaction problem | 35 | 7% | 0.7% |
| Device dislodged or dislocated | 31 | 6.2% | 0.6% |
| Positioning problem | 22 | 4.4% | 0.8% |
| Occlusion within devicethe device blocked | 20 | 4% | 5.4% |
| Difficult to advance | 19 | 3.8% | 0.6% |
| Loosening of implant not related to bone-ingrowth | 14 | 2.8% | 0.1% |
| Physical resistance/sticking | 14 | 2.8% | 0.2% |
| Device tipped over | 13 | 2.6% | 0% |
| Activation, positioning or separation problem | 12 | 2.4% | 1.7% |
| Fluid/blood leak | 12 | 2.4% | 1.8% |
| Loss of or failure to bond | 12 | 2.4% | 0.3% |
| Insufficient device problem information | 11 | 2.2% | 6.4% |
| Entrapment of device | 8 | 1.6% | 0.2% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Clinical endoleak | 101 | 20.2% |
| Appropriate clinical signs, symptoms and conditions term/code not available | 52 | 10.4% |
| Thrombosis/thrombus | 37 | 7.4% |
| Deaththe patient died; cause not stated by this term | 24 | 4.8% |
| Vascular dissection | 24 | 4.8% |
| Thrombus | 19 | 3.8% |
| Aneurysm | 9 | 1.8% |
| Cardiac arrestthe heart stopped | 9 | 1.8% |
| Hemorrhage/blood loss/bleeding | 9 | 1.8% |
| Thrombosis | 9 | 1.8% |
| Obstruction/occlusion | 8 | 1.6% |
| Paraplegia | 8 | 1.6% |
| Aneurysm expansion | 7 | 1.4% |
| Rupturethe device burst | 7 | 1.4% |
| Ruptured aneurysm | 7 | 1.4% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Zenith Alpha Thoracic Endovascular Graft Proximal Components | Product code MIH | All MAUDE reports |
|---|---|---|---|
| Reports | 500 | 72,039 | 26,136,888 |
| Share of that pool | — | 0.7% | 0% |
| Classified as death, per 1,000 reports | 82 | 98 | 9 |
| Classified as injury | 55.8% | 74.9% | 36.2% |
| Classified as malfunction | 36% | 14.8% | 62.3% |
| Filed by the manufacturer | 93.2% | 99% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code MIH
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| GORE EXCLUDER AAA Endoprosthesis | 9,590 | 633 | 4.8% |
| Afx | 3,584 | 30 | 5% |
| Gore Tag Thoracic Endoprosthesis | 2,829 | 4 | 14.7% |
| Endurant | 1,861 | 0 | 14.7% |
| Endurant Iis Bifurcated Stent Graft | 1,706 | 121 | 11.6% |
| Valiant Captivia - FF | 1,532 | 95 | 15.1% |
| GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System | 1,474 | 311 | 7.7% |
| Endurant Stent Graft | 1,471 | 56 | 10% |
| Afx2 | 1,263 | 123 | 6.4% |
| Medtronic Aneurx Bifurcated Stent Graft Flexible | 1,263 | 0 | 9.7% |
| Zenith Flex AAA Endovascular Graft Bifurcated Main Body | 1,172 | 15 | 6.1% |
| Valiant Navion | 1,149 | 40 | 17.4% |
| Ancure Endograft System | 1,126 | 0 | 5.1% |
| Endurant Abdominal Stent Graft System | 997 | 0 | 12.9% |
| Afx System | 882 | 0 | 8.4% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Zenith Alpha Thoracic Endovascular Graft Proximal Components reports
How many FDA reports name Zenith Alpha Thoracic Endovascular Graft Proximal Components?
500 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 45 in the latest 12 months.
What kinds of events are reported?
injury (55.8%), malfunction (36%) and death (8.2%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
off-label use (19.4%), failure to advance (8.8%), malposition of device (8.4%), device endoleak (8%) and leak/splash (7.6%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (93.2%) and distributor reports (6.8%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Zenith Alpha Thoracic Endovascular Graft Proximal Components was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.